Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder

  title={Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder},
  author={John W. G. Tiller and Colin Bouwer and Kirsten Behnke},
  journal={International Clinical Psychopharmacology},
Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxctine. The target dose of moclobemide was 450 mg/day in the dose range of 300–600 mg/day, while the target dose for fluoxetine was 20… Expand
The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder
In conclusion, moclobemide in a dose of 450 mg per day seems to be a good drug alternative for treatment of panic disorder with and withouth agoraphobia. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Psychopharmacology of anxiety disorders
This comprehensive practical review summarizes current therapeutic research across the spectrum of individual disorders: generalized anxiety disorder (GAD), panic disorder (PD) and agoraphobia (social anxiety disorder), compulsive disorder (OCD), phobic disorder (including social phobia), and posttraumatic stress disorder (PTSD). Expand
Pharmacological Treatment of Panic Disorder with Non-Selective Drugs
It is important to use existing scientific evidences regarding effectiveness, tolerability and safety, combined with clinical experience, to plan a rational treatment sequence for panic disorder patients. Expand
Post-Marketing Study for the Safety and Effectiveness of Moclobemide Among Patients with Depression in Family Practice Outpatient Clinic
The percentage of adherence at 12th week of Moclobemide among patients suffering from depression in the family practice outpatient clinic was shown to be 49%. Expand
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
The benzamide moclobemide's evolution, pharmacodynamic and pharmacokinetic properties are focused on, including the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. Expand
Clonidine in respiratory panic disorder subtype.
Clonidine can be effective in the treatment of respiratory PD and might play a role in relieving symptoms of anxiety due to noradrenergic hyperactivity in these patients. Expand
The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety.
The ideal anxiolytic does not exist, but research with other new compounds is very active, and some experimental drugs show promise for the future. Expand
Neuropsychopharmacology : The Fifth Generation of Progress 968 through the pharmacologic dissection work of
During the 1960s and 1970s the concept of ‘‘pharmacologic dissection’’ became popular as a putative method for differentiating among different categories of psychiatric illness. At the time, it wasExpand
A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia.
There was a statistically significant difference favoring risperidone on the change at endpoint on the Positive and Negative Syndrome Scale (PANSS) positive symptoms subscale (an a priori secondary efficacy measure) in that double-blind, 8-week study, and complementary results from these 2 independent studies support an efficacy benefit with ris peridone compared with quetiapine for positive symptoms. Expand